Relay Therapeutics, Inc. (RLAY)

NASDAQ: RLAY · Real-Time Price · USD
3.000
+0.050 (1.69%)
May 8, 2025, 4:00 PM EDT - Market closed
1.69%
Market Cap 514.33M
Revenue (ttm) 7.68M
Net Income (ttm) -333.39M
Shares Out 171.44M
EPS (ttm) -2.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,622,742
Open 2.945
Previous Close 2.950
Day's Range 2.705 - 3.065
52-Week Range 1.775 - 10.720
Beta 1.65
Analysts Strong Buy
Price Target 18.40 (+513.33%)
Earnings Date May 5, 2025

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2020
Employees 261
Stock Exchange NASDAQ
Ticker Symbol RLAY
Full Company Profile

Financial Performance

In 2024, Relay Therapeutics's revenue was $10.01 million, a decrease of -60.83% compared to the previous year's $25.55 million. Losses were -$337.71 million, -1.25% less than in 2023.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price forecast is $18.4, which is an increase of 513.33% from the latest price.

Price Target
$18.4
(513.33% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...

9 hours ago - GlobeNewsWire

Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu...

3 days ago - GlobeNewsWire

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

10 days ago - GlobeNewsWire

Relay Therapeutics: Trying To Find That Right Price

Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, sho...

26 days ago - Seeking Alpha

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer

2 months ago - GlobeNewsWire

Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

2 months ago - GlobeNewsWire

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q...

2 months ago - Seeking Alpha

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

4 months ago - GlobeNewsWire

Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D

5 months ago - GlobeNewsWire

Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET

5 months ago - GlobeNewsWire

Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

5 months ago - GlobeNewsWire

Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

5 months ago - GlobeNewsWire

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D

6 months ago - GlobeNewsWire

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...

6 months ago - GlobeNewsWire

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast c...

8 months ago - Seeking Alpha

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mu...

8 months ago - Seeking Alpha

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Wednesday.

Other symbols: GMEWOOF
8 months ago - Benzinga

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

8 months ago - GlobeNewsWire

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib o...

8 months ago - Benzinga

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Other symbols: JCIDKEQRORCL
8 months ago - Benzinga

Relay Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...

8 months ago - GlobeNewsWire

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher

U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday.

8 months ago - Benzinga

Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients

Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics a...

8 months ago - Benzinga

Relay Therapeutics' combo therapy for breast cancer cuts disease progression in early study

Relay Therapeutics said on Monday interim data from an early-stage study of its experimental combination treatment for breast cancer showed it meaningfully extended the time patients lived without the...

8 months ago - Reuters

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival

9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favo...

8 months ago - GlobeNewsWire